Lepodisiran is a small interfering RNA that was developed to reduce lipoprotein in people at risk of cardiovascular disease. It was developed by Eli Lilly and Company. From Wikipedia
The siRNA-based drug shows promise as the first potential treatment for lipoprotein(a), a major cardiovascular risk factor, with Phase 3 trials now underway.
